The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Good find Muck. I think you might be right!
Ref the America chat, Abingdon have a very bold statement on their website
"Abingdon Health is a world leading lateral flow rapid diagnostics business to all industry sectors and is a rapid test manufacturer of choice for the USA and Canada."
Rapid test manufacturer of choice for the USA and Canada really does give the impression this market will be huge for Abingdon. I'd love for them to elaborate but I guess we will have to wait for it all to become clear.
https://www.abingdonhealth.com/services/usa-canada/?utm_campaign=US%20landing%20page&utm_content=159120155&utm_medium=social&utm_source=twitter&hss_channel=tw-2194239800
you work in primary care (for example a GP, pharmacist, community nurse, dental nurse or optician)
you do any job in a care home
you’re a care worker in paid domiciliary care (caring for people in their homes)
It seems Bupa offer an antibody service at £65 per test.
Its worth noting in Bupa FAQ they mention:
'The relative sensitivity (true positive) of the test 97.95% vs ELISA (enzyme-linked immunoassay). The relative specificity (true negative) is 99.57% vs ELISA. The overall accuracy of the test is 99.25%'
https://www.bupa.co.uk/health/payg/covid-testing
Abingdon Health website mentions results for ABC-19 Antibody test:
1. When using methods as used in previous evaluations by PHE1, results for the AbC-19TM IgG test of 92.5% sensitivity and 97.9%* specificity are in line with those other tests. (This rose to *99.2% specificity when queried samples were repeated. *This increase in specificity relates to 42 positives out of 1995 presumed negative samples (collected in 2016-2017) which drop to 16 positives on repeat testing).https://www.abingdonhealth.com/news/abc-19-response-to-media/
97.95% sensitivity (True positive) seems very similar to 97.9% specificity that Abingdon mention.
So does Bupas mentioned overall accuracy of 99.25% compared with Abingdon 99.2% overall specificity.
https://www.dailymail.co.uk/news/article-9404085/Fury-plans-Covid-pub-passport-app-proof-jab-negative-test-immunity.html
Daily mail running with article also
Get an antibody test kit from Gov.uk
This is the start of the UK’s at-home antibody test kit programme.
Antibody test kits are not widely available.
You can still get an antibody test if you’ve had the coronavirus (COVID-19) vaccine.
Eligibility depends on the job you do and where you live in the UK.
https://www.gov.uk/government/publications/coronavirus-covid-19-antibody-tests/coronavirus-covid-19-antibody-tests
Get an antibody test kit from Gov.uk
This is the start of the UK’s at-home antibody test kit programme.
Antibody test kits are not widely available.
You can still get an antibody test if you’ve had the coronavirus (COVID-19) vaccine.
Eligibility depends on the job you do and where you live in the UK.
https://www.gov.uk/government/publications/coronavirus-covid-19-antibody-tests/coronavirus-covid-19-antibody-tests
The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium (UK-RTC), has received its CE mark. This means it is approved for professional use in the UK and EU.
https://www.abingdonhealth.com/news/uk-covid-19-rapid-antibody-tests-approved-for-professional-use/
Britain has more than 30million 15-minute pin-prick kits to test antibodies in the blood — evidence of previous infection — ready to be rolled out this summer.
Whos tests i wonder?
https://www.thesun.co.uk/news/14458730/covid-survivors-immunity-freedom-pass/amp/
https://www.ukbiobank.ac.uk/explore-your-participation/contribute-further/coronavirus-self-test-antibody-study-phase-2/frequently-asked-questions-phase-2
BIOBANK are using the ABC-19 test for a MHRA study into long covid. This study is a home use study. Its finally getting airtime! Check out this below from the FAQ section:
What is the AbC-19 Rapid TM Test?
The AbC-19 Rapid TM Test is a single-use test for the detection of SARS-CoV-2 IgG antibodies in capillary blood. The test requires a small drop of blood from a finger-prick and shows results in 20 minutes, without the need to send a sample to a laboratory.
Who bought the antibody test kits?
The kits were donated to UK Biobank by the Department of Health and Social Care.
Why are two different test kits (the Fortress Fast COVID-19 Device and the AbC-19 Rapid TM Kit) being used for phase 1 and phase 2 of this antibody self-test study?
In order to start the study as quickly as possible, we used the Fortress Fast COVID-19 Device in phase 1 of the study (which took place February-March) as this device has been used in other research studies and we were able to obtain rapid regulatory approval for its use in UK Biobank. The AbC-19 Rapid TM kit being used in phase 2 (the current phase of the study) took longer to obtain the necessary approvals for use. Both kits can detect whether you have antibodies to the SARS-CoV-2 virus.
Will I receive the results from my test?
Yes. You will be able to see the outcome of the antibody test within 20 minutes. We would like you to send us the result of your test as soon as possible after you have done it. As with all antibody tests, the results are not 100% accurate and should not be used to guide your behaviour. A positive test does not necessarily mean you have had COVID-19 and it is important that you continue to follow the current government COVID-19 legislation and guidance. If you are worried about currently having COVID-19, you should follow the current government/NHS guidance about obtaining a diagnostic test or call 111.
I have read that antibody tests do not work. Is that true?
The AbC-19TM Rapid Test detects IgG antibodies to SARS-CoV-2 in the blood. The device has been developed by Abingdon Health and is registered for research purposes (as in this study) with the Medical and Healthcare products Regulatory Agency (MHRA).
There are certain circumstances in which a false negative result may occur (i.e. where the test does not identify antibodies even though you have been infected previously with the virus), including if the test is performed less than 14 days after the first signs of infection.
* apologies, should read Abingdon developed the ABC-19 test.
ODX are not equal partners when it comes to profit share.
The contract states 'ODX will manufacture no less then 25% of ABC-19 production'. Manufacture being the key word here.
ABC-19 developed the test and therefore expect them to take a large share of profits. ODX is simply sub contracted to manufacture. I expect 75p per test produced is what ODX are looking at.
https://twitter.com/OmegaDiagnostic/status/1359761193620103168
Earlier Feb Tweet from ODX states 2 mil per week by the end of April. Not deramping, just fact checking.
Never know, could be on track to get equipment set up faster but dont lose faith if we dont see this volume produced until end of April as stated by Omega.
ABC-19 RNS from 24 Feb 21 about a study alongside the Pfizer vaccine stated 'further studies are being performed to expand this data set and are expected to be available in the next few weeks.'
Well its now been 1 Month so i expect we will hear about news from this more indepth study soon!
https://www.londonstockexchange.com/news-article/ODX/uk-rtc-statement-on-abc-19tm-rapid-antibody-test/14876208?lang=en
https://www.ukbiobank.ac.uk/explore-your-participation/contribute-further/coronavirus-self-test-antibody-study-phase-2/frequently-asked-questions-phase-2
BIOBANK are using the ABC-19 test for a MHRA study into long covid. This study is a home use study. Its finally getting airtime! Check out this below from the FAQ section:
What is the AbC-19 Rapid TM Test?
The AbC-19 Rapid TM Test is a single-use test for the detection of SARS-CoV-2 IgG antibodies in capillary blood. The test requires a small drop of blood from a finger-prick and shows results in 20 minutes, without the need to send a sample to a laboratory.
Who bought the antibody test kits?
The kits were donated to UK Biobank by the Department of Health and Social Care.
Why are two different test kits (the Fortress Fast COVID-19 Device and the AbC-19 Rapid TM Kit) being used for phase 1 and phase 2 of this antibody self-test study?
In order to start the study as quickly as possible, we used the Fortress Fast COVID-19 Device in phase 1 of the study (which took place February-March) as this device has been used in other research studies and we were able to obtain rapid regulatory approval for its use in UK Biobank. The AbC-19 Rapid TM kit being used in phase 2 (the current phase of the study) took longer to obtain the necessary approvals for use. Both kits can detect whether you have antibodies to the SARS-CoV-2 virus.
Will I receive the results from my test?
Yes. You will be able to see the outcome of the antibody test within 20 minutes. We would like you to send us the result of your test as soon as possible after you have done it. As with all antibody tests, the results are not 100% accurate and should not be used to guide your behaviour. A positive test does not necessarily mean you have had COVID-19 and it is important that you continue to follow the current government COVID-19 legislation and guidance. If you are worried about currently having COVID-19, you should follow the current government/NHS guidance about obtaining a diagnostic test or call 111.
I have read that antibody tests do not work. Is that true?
The AbC-19TM Rapid Test detects IgG antibodies to SARS-CoV-2 in the blood. The device has been developed by Abingdon Health and is registered for research purposes (as in this study) with the Medical and Healthcare products Regulatory Agency (MHRA).
There are certain circumstances in which a false negative result may occur (i.e. where the test does not identify antibodies even though you have been infected previously with the virus), including if the test is performed less than 14 days after the first signs of infection.
True, I guess its just an extra bonus to have more partners to manufacture for, when they are ready to produce we are ready.
In reference to the nasal swab and the UK not wanting it . . . . I agree, I mentioned the CE Mark 'market' is huge, i should have elaborated I think the market they will target will be Europe with that test.
Abingdon has so much going for it yet they seem far to modest and quiet right now. I would like to see more articles / positive press releases and I think those are coming once contracts are announced. I wonder if their is a slice of the £8 bil tender next month too.
Once we see the Abingdon AppDX come to fruition i guess all will be clear what tests it works with and indicate what we are manufacturing.
https://www.abingdonhealth.com/services/usa-canada/?utm_campaign=US%20landing%20page&utm_content=159120155&utm_medium=social&utm_source=twitter&hss_channel=tw-2194239800
RAPID TEST MANUFACTURER - USA AND CANADA - seems they are making all the right moves!
Lets discuss the huge link to Sona Nanotech that looks promising:
1. Sona are already partnered with Abingdon and Bond Health UK
2. Bond Health UK are working with the Abingdon AppDX LFT App and all the pictures/marketing/videos use the SONA labelled LFT.
3. Sona LFT mentioned in December that they have CE Mark and a UK manufacturer , In January Abingdon mentioned they have an international partner (all signs pointing to Abingdon + Sona).
4. Sona are based in Novia Scotia and also York, Abingdon are based in York and are looking to expand in North America . . . . . Coincidence???
5. Sona mention TT complete with a UK manufacturer.
6. Also links with BBI and Sona with the Ex BBI CEO moving across to Sona so i expect BBI are in the mix too - Previous news articles claim Abingdon and BBI will have a 7 Mil a month capability to produce LFTs.
Lastly, its worth mentioning the size of the market that you can sell to with a CE Mark is huge!
Its worth posting again. Recent RNS . . . So positive!
Post-period operational highlights:
· Completed delivery of 1m units of AbC-19™ COVID-19 rapid antibody test to the Department of Health and Social Care (DHSC);
· Completed delivery of 1m units of our PCRD device, a nucleic acid lateral flow immunoassay (NALFIA), to a customer in the U.S.;
· Contract agreed in January 2021 for technical transfer to manufacture of a COVID-19 antigen test for a customer in the UK;
· Resubmission of AbC-19™ data for US FDA Emergency Use Authorization (EUA);
· Good commercial progress with AbC-19™ COVID-19 rapid antibody test being evaluated in over 30 countries worldwide, with several contracts in late-stage negotiations subject to registration;
· Stage 2 of York and Doncaster capacity expansion builds underway and planned for completion by April 2021;
· Appointment of Melanie Ross as Chief Financial Officer and to the Board;
· Collaboration and co-marketing agreement signed with Abcam plc;
· Grant of AppDx patent around use of artificial intelligence and machine learning in reading lateral flow tests with smartphones; and
· Initial test data shows the effectiveness of AbC-19™ COVID-19 rapid antibody test in demonstrating immune response of patients to the first dose of the Pfizer-BioNTech COVID-19 vaccine.
Chris Yates, CEO at Abingdon Health PLC, commented:
"I am pleased to report Abingdon Health's maiden set of interim results since our listing on the AIM market in December 2020. Over the past six months, the Company has made significant commercial progress across the COVID-19 and non-COVID-19 commercial pipeline and, operationally, Abingdon Health has successfully completed the first phase of its manufacturing expansion. Due to the growing global demand for lateral-flow tests, the Company is continuing to scale up and is on track to be able to produce 150 million tests per annum by the end of 2021.
Over recent weeks, there has been growing evidence that rapid antibody testing can be used to determine an individual's antibody status both prior to and after vaccination, a crucial factor in stratifying patients and determining resource allocation on overburdened health systems. As a result of this, and the leading accuracy of Abingdon Health's test, the Company anticipates an increased demand for rapid antibody tests that can be used as a companion to COVID-19 vaccines.
Whilst the timing of any antibody testing programme roll-outs and future orders are difficult to accurately predict given the range of factors that the Company is dealing with from, inter alia, the evolving regulatory processes and the impact of COVID-19 virus mutations, the Board remains confident in both the short and medium-term growth opportunities. The Company's Tier 1 order pipeline for AbC-19TM continues to grow and this gives the Board the confidence in the Company's ability to achi
https://www.zephyrplc.com/investors/significant-shareholders/
Origin Creek Energy LLC own 18.95% of Zephyr.
Colin Harrington (Director) is indirectly the controlling shareholder of Origin Creek Energy LLC (“OCE”). Rick Grant (Director) is a 19% shareholder of OCE.
Origin Creek Energy LLC* Director / Investor 18.95%
Chris Eadie Director 0.76%
Gordon Stein Director 0.27%
Tom Reynolds Director 0.14%
Spreadex Private Investor 3.03%
G.P. (Jersey) Limited Investor 4.00%
Tyndall Investment Management Investor 3.72%
Flute Investments Investor 3.48%
Shares not considered to be in public hands: 20.12%